Axsome Therapeutics Inc
AXSM102.645USD
-0.375-0.36%
交易中 （美东）报价延迟15分钟
5.05B总市值
亏损市盈率 TTM
关于 Axsome Therapeutics Inc 公司
Axsome Therapeutics, Inc. 是一家商业阶段的生物制药公司。该公司致力于开发和提供针对中枢神经系统 (CNS) 的疗法，这些疾病的治疗选择有限。该公司的两种商业产品和开发项目是 Auvelity 和 Sunosi。Auvelity（右美沙芬-布丙酮）是一种口服 N-甲基-D-天冬氨酸 (NMDA) 受体拮抗剂，具有多模态活性，用于治疗重度抑郁症 (MDD)。Sunosi (solriamfetol) 是一种口服药物，用于治疗发作性睡病或阻塞性睡眠呼吸暂停患者的过度日间嗜睡 (EDS)。AXS-05 是一种口服、研究性 NMDA 受体拮抗剂，具有多模态活性，正在开发用于治疗阿尔茨海默病躁动 (AD 躁动) 和戒烟。 AXS-07 是一种口服、快速吸收、多机制的试验药物，正在开发用于治疗偏头痛的急性治疗。
公司简介
公司代码AXSM
公司名称Axsome Therapeutics Inc
上市日期Nov 19, 2015
CEODr. Herriot Tabuteau, M.D.
员工数量683
证券类型Ordinary Share
年结日Nov 19
公司地址One World Trade Center, 29Th Floor
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编10007
电话12123323241
网址https://www.axsome.com/
公司代码AXSM
上市日期Nov 19, 2015
CEODr. Herriot Tabuteau, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
业务USD
名称
营收
占比
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
地区USD
名称
营收
占比
United States
119.41M
98.31%
Outside of the United States
2.05M
1.69%
业务
地区
业务USD
名称
营收
占比
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
股东统计
更新时间: 7月12日 周六
更新时间: 7月12日 周六
持股股东
股东类型
持股股东
持股股东
占比
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
持股股东
持股股东
占比
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
股东类型
持股股东
占比
Investment Advisor
33.54%
Investment Advisor/Hedge Fund
22.21%
Corporation
14.92%
Hedge Fund
14.24%
Research Firm
2.73%
Private Equity
1.51%
Individual Investor
1.39%
Pension Fund
1.17%
Sovereign Wealth Fund
0.82%
Other
7.48%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
614
46.10M
93.63%
-4.69M
2025Q1
613
46.35M
94.71%
-3.83M
2024Q4
570
46.09M
94.52%
-5.46M
2024Q3
540
47.31M
97.60%
-6.48M
2024Q2
526
49.58M
103.45%
-2.44M
2024Q1
512
47.53M
101.57%
-4.95M
2023Q4
484
47.45M
101.62%
-3.96M
2023Q3
475
47.05M
100.91%
-2.63M
2023Q2
475
45.53M
98.82%
+628.64K
2023Q1
467
40.73M
95.65%
-3.70M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Antecip Capital, L.L.C.
7.34M
14.92%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.87M
7.86%
-26.20K
-0.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
6.03%
-40.30K
-1.34%
Mar 31, 2025
RTW Investments L.P.
2.92M
5.94%
-1.13M
-27.86%
Mar 31, 2025
BVF Partners L.P.
1.69M
3.43%
+302.16K
+21.77%
Mar 31, 2025
Macquarie Investment Management
976.26K
1.98%
+12.21K
+1.27%
Mar 31, 2025
Geode Capital Management, L.L.C.
934.85K
1.9%
+22.32K
+2.45%
Mar 31, 2025
Fidelity Management & Research Company LLC
916.73K
1.86%
+275.45K
+42.95%
Mar 31, 2025
State Street Global Advisors (US)
906.02K
1.84%
-41.23K
-4.35%
Mar 31, 2025
Fairmount Funds Management LLC
815.18K
1.66%
-653.81K
-44.51%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
SPDR S&P Pharmaceuticals ETF
3.7%
ALPS Medical Breakthroughs ETF
3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.62%
Tema Neuroscience and Mental Health ETF
2.52%
iShares U.S. Pharmaceuticals ETF
2.17%
Virtus LifeSci Biotech Products ETF
1.89%
First Trust Mid Cap Growth AlphaDEX Fund
0.6%
iShares Health Innovation Active ETF
0.59%
Invesco Nasdaq Biotechnology ETF
0.57%
ProShares Ultra Nasdaq Biotechnology
0.57%
查看更多
SPDR S&P Pharmaceuticals ETF
占比3.7%
ALPS Medical Breakthroughs ETF
占比3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比2.62%
Tema Neuroscience and Mental Health ETF
占比2.52%
iShares U.S. Pharmaceuticals ETF
占比2.17%
Virtus LifeSci Biotech Products ETF
占比1.89%
First Trust Mid Cap Growth AlphaDEX Fund
占比0.6%
iShares Health Innovation Active ETF
占比0.59%
Invesco Nasdaq Biotechnology ETF
占比0.57%
ProShares Ultra Nasdaq Biotechnology
占比0.57%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
